Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by ANALIAS00on May 16, 2019 7:44am

97 Views

Post# 29751357

RE:RE:RE:Actively assessing a Nasdaq Listing???

Nasdac comment came as an answer from a question if i am not mistaken. About Trogarzo surpassing Egrifta their was no doupt that this "guidance" repeated several time would be met.

palinc2000 wrote:
Thx for the additional color!
Still the Nasdaq comment in the PR is odd.What is their goal in mentioning
Nasdaq before a decidion has been reached?

Also given the outstanding top line results in the Grinspoon study it is surprising that they have not been contacted by a major Nash player.
Maybe the release of the detailed results will be the trigger...
One last thing ...... how do you interpret Luc ‘s comment about having reached the goal of Trogarzo surpassing Egrifta? Do you rxpect Trogarzo sales to be at least equal to Egrifta in the second Quarter?

SPCEO1 wrote: I think I can clear some things up for you since I was at the AGM. They indicated they have not been approached by any other company so far as a result of the NASH results.They have been developing relationships with US brokers for quite some time now and likely don't need to solicit offers from them. They also indicated they would go it alone in HIV NASH but would probably partner if they pursue a general NASH approval.

palinc2000 wrote: This statement in the PR is so out of character for Luc that I think it is subject to interpretation and speculation
1-Is it a negotiation ploy for Nash ? Their way of telling an acquirer for the rights of Egrifta we have other options
2- Is it a way to sollicit offers from US Brokers for an eventual Offering?
3-Is it Luc s way to tell us that going solo on Nash was always the Plan just in case they dont get any offers for Nash from big pharmas?

BTW the statement at an AGM for the first time is not a normal way ,,,,,